LEXICON PHARMACEUTICALS INC's ticker is LXRX and the CUSIP is 528872302. A total of 113 filers reported holding LEXICON PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,000 | -16.7% | 13,778 | +74.3% | 0.00% | – |
| Q2 2023 | $18,000 | +63.6% | 7,907 | +69.7% | 0.00% | – |
| Q1 2023 | $11,000 | -54.2% | 4,660 | -63.1% | 0.00% | – |
| Q4 2022 | $24,000 | +1100.0% | 12,620 | +1119.3% | 0.00% | – |
| Q3 2022 | $2,000 | 0.0% | 1,035 | +12.5% | 0.00% | – |
| Q2 2022 | $2,000 | -80.0% | 920 | -80.9% | 0.00% | – |
| Q1 2022 | $10,000 | -81.5% | 4,811 | -65.1% | 0.00% | – |
| Q4 2021 | $54,000 | +74.2% | 13,786 | +106.5% | 0.00% | – |
| Q3 2021 | $31,000 | +34.8% | 6,677 | +28.8% | 0.00% | – |
| Q2 2021 | $23,000 | -14.8% | 5,185 | +11.5% | 0.00% | – |
| Q1 2021 | $27,000 | +575.0% | 4,652 | +283.8% | 0.00% | – |
| Q4 2020 | $4,000 | +100.0% | 1,212 | -26.8% | 0.00% | – |
| Q3 2020 | $2,000 | -33.3% | 1,655 | +28.1% | 0.00% | – |
| Q2 2020 | $3,000 | -57.1% | 1,292 | -64.0% | 0.00% | – |
| Q1 2020 | $7,000 | +133.3% | 3,593 | +503.9% | 0.00% | – |
| Q4 2019 | $3,000 | +50.0% | 595 | -23.5% | 0.00% | – |
| Q3 2019 | $2,000 | -60.0% | 778 | +5.3% | 0.00% | – |
| Q2 2019 | $5,000 | +25.0% | 739 | -2.6% | 0.00% | – |
| Q1 2019 | $4,000 | +100.0% | 759 | +145.6% | 0.00% | – |
| Q4 2018 | $2,000 | -84.6% | 309 | -74.4% | 0.00% | – |
| Q3 2018 | $13,000 | +116.7% | 1,205 | +156.4% | 0.00% | – |
| Q2 2018 | $6,000 | -40.0% | 470 | -60.4% | 0.00% | – |
| Q1 2018 | $10,000 | +42.9% | 1,186 | +79.7% | 0.00% | – |
| Q4 2017 | $7,000 | -87.9% | 660 | -86.1% | 0.00% | – |
| Q3 2017 | $58,000 | +866.7% | 4,755 | +1231.9% | 0.00% | – |
| Q2 2017 | $6,000 | -75.0% | 357 | -77.6% | 0.00% | – |
| Q1 2017 | $24,000 | +20.0% | 1,597 | +8.0% | 0.00% | – |
| Q4 2016 | $20,000 | -93.7% | 1,479 | -91.6% | 0.00% | – |
| Q3 2016 | $319,000 | -11.9% | 17,686 | -29.7% | 0.00% | – |
| Q2 2016 | $362,000 | -5.0% | 25,174 | -21.0% | 0.00% | – |
| Q1 2016 | $381,000 | +3363.6% | 31,886 | +3961.9% | 0.00% | – |
| Q4 2015 | $11,000 | -57.7% | 785 | -67.2% | 0.00% | – |
| Q3 2015 | $26,000 | 0.0% | 2,393 | -26.3% | 0.00% | – |
| Q2 2015 | $26,000 | – | 3,247 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ulys, L.L.C. | 4,321,214 | $25,366,000 | 100.00% |
| Artal Group S.A. | 71,178,364 | $417,817,000 | 7.38% |
| BVF INC/IL | 8,394,000 | $49,273,000 | 1.85% |
| Boothe Investment Group, Inc. | 435,939 | $2,559,000 | 1.49% |
| Campbell & CO Investment Adviser LLC | 103,100 | $605,000 | 0.37% |
| NEA Management Company, LLC | 2,382,286 | $13,984,000 | 0.31% |
| PINNACLE ASSOCIATES LTD | 2,167,172 | $12,721,000 | 0.24% |
| Eversept Partners, LP | 410,593 | $2,410,181 | 0.18% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 35,714 | $210,000 | 0.12% |
| OCCUDO QUANTITATIVE STRATEGIES LP | 66,299 | $389,000 | 0.08% |